Abstract
Certolizumab pegol is a new anti-TNF-alpha inhibitor which has been approved for the treatment of rheumatoid arthritis since October 2009. Due to the modification of the antibody fragment by the adherence of polyethylene glycol (PEG) a sufficient distribution in inflammatory tissue was found in animal experiments. In two individual case reports a remission of therapy refractive arthritis was achieved by administration of certolizumab pegol.
MeSH terms
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Arthritis, Rheumatoid / diagnosis*
-
Arthritis, Rheumatoid / drug therapy*
-
Certolizumab Pegol
-
Female
-
Humans
-
Immunoglobulin Fab Fragments / therapeutic use*
-
Middle Aged
-
Polyethylene Glycols / therapeutic use*
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin Fab Fragments
-
Polyethylene Glycols
-
Certolizumab Pegol